About US
關于我們
1992
Hainan Poly Pharm was Founded
1995
Poly Launched its First Product Nimodipine Capsules to Market
2003
Zhejiang Poly Pharm was Established
2005
cGMP Certification Launched to Start a New Journey of Internationalization
2011
Production Line of Ganciclovir Sodium for Injection and its API Passed WHO on-site GMP Inspection
2012
1. Hainan Poly Pharm Changed to be a Joint-stock Company；
2. Production Line of Ganciclovir Sodium for Injection and its API Passed EU EMA On-site GMP Inspection；
3. Product Approved to WHO pre-qualification Program
2014
Ganciclovir sodium for injection receives EU marketing authorization
2015
Production Line of Lyophilized Powder Injection Passed US FDA Inspection
2016
EU Marketing Authorization Obtained for Levetiracetam Injection
2017
Poly Pharma Successfully Listed in Growth Enterprise Board
2018
1. Facility of Hangzhou Poly Pharm Put into Operation；
2. New Injection Building and Upgraded API Workshop of Hainan Poly Pharm Put into Operation；
3. API Workshop and Lyophilized Injection Line Passed WHO GMP Follow-up Inspection
2019
Anhui Poly Pharm Laid Foundation Stone for its Manufacturing Facility
2020
1. First Shippment of Sodium Nitroprusside Injection to the United States；
2. Bivalirudin for Injection Approved for Marketing in China；
3. Ganciclovir Sodium for Injection Passed Consistency Evaluation.
2021
1. Zhejiang Poly Pharm received EIR for its first pre-approval inspection by FDA
2. Beijing Pharmaceutical Innovation Platform was jointly established by Institute of High Energy Physics (Chinese Academy of Sciences) and Poly Pharm.
3. Poly Pharma Steps into DNA Vaccine；
4. Anqing facility officially start production。
2022
1、Celebrating 30th Anniversary of Poly Pharm Group (1992-2020)；
2、Initial Shippment of Esomeprazole Sodium for Injection to the United States；
3、Sodium Nitroprusside Injection passed the evaluation of bio-equivalence consisteny and approved for marketing in China.
Home